Alexis Pinto - 10 Feb 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Legal Officer
Signature: /s/ Melissa B. Epperly, Attorney-in-Fact for Alexis Pinto
Issuer symbol: ZNTL
Transactions as of: 10 Feb 2022
Net transactions value: -$34,708
Form type: 4
Filing time: 14 Feb 2022, 20:10:22 UTC
Previous filing: 27 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+16,405	+251%	$0.000000	22,931	10 Feb 2022	Direct	F1
transaction	ZNTL	Common Stock	Sale	$30,801	-614	-2.7%	$50.16	22,317	14 Feb 2022	Direct	F2, F3
transaction	ZNTL	Common Stock	Sale	$3,908	-77	-0.35%	$50.75	22,240	14 Feb 2022	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+38,489		$0.000000	38,489	10 Feb 2022	Common Stock	38,489	$52.61	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2	The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F3	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.